Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma

CONCLUSIONS: Abemaciclib was well tolerated and showed promising activity in DDLS. The discovery of ANGPTL4 as a late regulator of geroconversion helped to define how cellular senescence modulates the immune tumor microenvironment and contributes to both positive and negative clinical outcomes.PMID:37695642 | DOI:10.1158/1078-0432.CCR-23-2378

Source: Clinical Cancer Research - September 11, 2023 Category: Cancer & Oncology Authors: Caroline E Gleason Mark A Dickson Mary E Klein Dooley Cristina R Antonescu Rodrigo Gularte-M érida Marimar Benitez Juliana I Delgado Raghu P Kataru Mark Wei Yi Tan Martina Bradic Travis E Adamson Kenneth Seier Allison L Richards Marta Palafox Eric Chan S Source Type: research